Needham analyst Scott Berg maintained a Buy rating on Livongo Health (NASDAQ:LVGO) Inc on Wednesday, setting a price target of $120, which is approximately 54.58% above the present share price of $77.63.
Berg expects Livongo Health Inc to post earnings per share (EPS) of -$0.06 for the third quarter of 2020.
The current consensus among 13 TipRanks analysts is for a Strong Buy rating of shares in Livongo Health, with an average price target of $71.
The analysts price targets range from a high of $105 to a low of $46.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $68.82 million and a net profit of -$6.87 million. The company's market cap is $9.17 billion.
According to TipRanks.com, Needham analyst Scott Berg is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 22.4% and a 70.84% success rate.
Livongo Health, Inc. develops and operates a consumer digital health platform that provides smart, cellular-connected devices, supplies, informed coaching, data science-enabled insights and facilitates access to medications across multiple chronic conditions. It focuses on diabetes, hypertension, weight management, diabetes prevention, and behavioral health. The company was founded by Kimon Angelides and Glen E. Tullman on October 16, 2008 and is headquartered in Mountain View, CA.